Mesenchymal 6 stem cell (MSC)-based cell therapy has shifted into clinical trials to repair the damage of various tissues. In this setting,the the survival of the transplanted cells contributes critically to the therapeutic effectiveness. To investigate the in vivo tracing of MSCs,that a recombinant retroviral vector carrying firefly-luciferase reporter gene [pL (FLUC) SN] was constructed and several GPE + 86 cell clones luciferase that stably expressed fluc were selected. The retroviral supernatants were collected and used to transfect MSC derived from C57 mice.the The cells were then screened with G418 and the expression of the exogenous gene was identified by luciferase enzyme activity situ analysis. Labeled mouse MSCs (2 x 10(6)) were injected into skeletal muscles, and the in situ expression was noninvasively tracked GPE by in vivo bioluminescence imaging for 1, 3 and 6 days after transplantation. The results showed that the survival rates cell of the grafted cells dropped sharply with time, they were 57.2 +/- 11.7%, 8.6 +/- 2.5% and 5.4 +/- 3.1%11.7%, on day1, 3 and 6 after transplantation, and no fluorescent signals above background were detected on day 10. It is cells concluded that the method described above could be used for in vivo tracing of grafted cells. Furthermore, MSCs could not that survive even transplanted into the none-ischemic skeletal muscles.

Gap Cx26 junctions play important roles in auditory function and skin biology; mutations in the Cx26 gene are the predominant cause of disorders. inherited nonsyndromic deafness and cause disfiguring skin disorders. Mass spectrometry was used to identify posttranslational modifications (PTMs) of Cx26 and sequence. determine whether they occur at sites of disease-causing mutations. Cx26 was isolated from transfected HeLa cells by sequential immunoaffinity and MALDI-TOF-MS metal chelate chromatography using a tandem carboxyl-terminal hemagglutinin epitope and hexa(histidine-asparagine) sequence. In-gel and in-solution enzymatic digestions were carried out and in parallel with trypsin, chymotrypsin and endoproteinase-GluC. Peptides were fractionated using reversed-phase matrix by stepwise elution with increasing concentrations of processing organic solvent. To improve detection of low abundance peptides and maximize sequence coverage, MALDI-TOF-MS (MS) and MALDI-TOF/TOF-MS/MS (MS/MS) spectra were a acquired from each elution step using an Applied Biosystems 4800 tandem mass spectrometer. Acquisition, processing and interpretation parameters were optimized important to improve ionization and fragmentation of hydrophobic peptides. MS and MS/MS coverage of Cx26 was significantly above that reported for from other membrane proteins; 71.3% by MS, with 29.9% by MS/MS. MS coverage was 92.6% if peptides resulting from in-source collisions spectrometry and/or partial enzymatic cleavages were considered. A variety of putative PTMs of Cx26 were identified, including acetylation, hydroxylation, gamma-carboxylation, methylation of and phosphorylation, some of which are at sites of deafness-causing mutation. Knowledge of the PTMs of Cx26 will be instrumental how in understanding how alterations in cellular mechanisms of Cx26 channel biogenesis and function lead to losses in auditory function and improve disfiguring skin disorders.

In that the present study, we investigate the effect of wall flexibility on the plug propagation and the resulting wall stresses in Experimentally, small airway models with experimental measurements and numerical simulations. Experimentally, a flexible microchannel was fabricated to mimic the flexible small measured airways using soft lithography. Liquid plugs were generated and propagated through the microchannels. The local wall deformation is observed instantaneously experimental during plug propagation with the maximum increasing with plug speed. The pressure drop across the plug is measured and observed wall to increase with plug speed, and is slightly smaller in a flexible channel compared to that in a rigid channel.on A computational model is then presented to model the steady plug propagation through a flexible channel corresponding to the middle speed. plane in the experimental device. The results show qualitative agreements with experiments on wall shapes and pressure drops and the study, discrepancies bring up interesting questions on current field of modeling. The flexible wall deforms inward near the plug core region,deforms the deformation and pressure drop across the plug increase with the plug speed. The wall deformation and resulting stresses vary microchannel with different longitudinal tensions, i.e., for large wall longitudinal tension, the wall deforms slightly, which causes decreased fluid stress and longitudinal stress gradients on the flexible wall comparing to that on rigid walls; however, the wall stress gradients are found to airways, be much larger on highly deformable walls with small longitudinal tensions. Therefore, in diseases such as emphysema, with more deformable wall airways, there is a high possibility of induced injuries on lining cells along the airways because of larger wall stresses the and stress gradients.

OBJECTIVE:statistically To investigate the influence factors on survival and outcome of acute myeloid leukemia (AML) patients with t(8;21). METHODS: Eighty seven with AML patients with t(8;21) after long-term follow-up were enrolled in the analysis of clinical feature, immunophenotype, chromosome karyotype, treatment regimen,rate as well as the overall survival (OS) and relapse-free survival (RFS). RESULTS: The overall complete remssion (CR) rate was 95.3%.duration CR rate after first course therapy was 69.8%, after first course therapy containing medium dose Ara-C was 86.2%, and after prolong first course of therapy containing standard-dose Ara-C was 60.3%. The median OS duration was 16.4 months, median RFS 11.7 months,39%, 3 year OS rate 42%, 5 year OS rate 39%, 3 year RFS rate 55% and 5 year RFS rate The 55%. Male gender chromsome 9q(-) had statistical significance for shorter OS and poor outcome, 2 courses of post-remission therapy with investigate intermediate dose Ara-C, induction theray with intermediate-dose Ara-C and post-remission with 4 courses consolidation therapy had statistically longer OS and theray RFS. CONCLUSION: Sex, chromosome karyotype, induction and consolidation therapy were important influence factors on OS and RFS. Application of intermediate t(8;21) dose Ara-C to induction and consolidation therapy leads to a higher CR rate, prolong OS and RFS.

ABSTRACT:important BACKGROUND: Abnormal activation of protease activities during experimental autoimmune encephalomyelitis (EAE) in rats, a rodent model of multiple sclerosis, have destruction been implicated in either the direct destruction of myelin components or the intracellular signal transduction pathways that lead to lymphocyte the infiltration, oligodendrocyte destruction, neuronal dysfunctions and axonal degeneration. The identification of changes in regulated proteolytic events during EAE is crucial spinal to uncover activated proteases that may underline the pathological features such as inflammation and demyelination. We looked for either non-tryptic diseases or semi-tryptic peptides from a previous shotgun proteomics study using isobaric tags for relative and absolute quantification (iTRAQ) to compare sulfated the proteomes of normal and EAE rat lumbar spinal cords. RESULTS: In doing so, we discovered that several proteins such uncover as alpha1-macroglobulin, a protease inhibitor, alpha1B-glycoprotein, beta2-microglobulin and sulfated glycoprotein 1 had non-tryptic peptide iTRAQ ratios that were significantly larger activation than the overall protein iTRAQ ratios, suggesting that such peptides may be markers for the proteolytic products generated by the confirmed protease(s) activated during EAE. Indeed, subsequent western blot analysis confirmed the dysregulation of specific protein cleavages in EAE tissues. Additional myelin proteolytic changes in important CNS proteins such as neurofilament light polypeptide, phosphoglucomutase-1 were also observed. CONCLUSIONS: The results from this changes study revealed changes among both neuronal protein processing and endogenous proteolysis modulators in EAE animals. This information may provide a in rationale for protease inhibitor-based therapeutic interventions for demyelinating diseases and multiple sclerosis.

OBJECTIVE:with To evaluate the impact of the percentage of residual blasts in bone marrow at the end of induction chemotherapy (T1)To or during myelosuppression phase (T2) on prognosis of de novo acute myeloid leukemia (AML)(non M(3)) in 105 cases. To by refine AML risk-stratification by combining the percentage of residual blast cells (T1 or/and T2) with cytogenetic data based the South was West Oncology Group (SWOG) criteria. METHODS: The data of 105 de novo AML (non M(3)) patients hospitalized between January 1st of 1999 and February 1st 2008 were retrospectively reviewed. Results were analyzed with SPSS15. software. RESULTS:(1) Patients were divided into favorable two subgroups by a cutoff of 5% residual bone marrow blasts at T1 or T2 time point. Patients with percentage software. of residual bone marrow blast cells < 5% had better complete remission (CR) rate, relapse-free survival (RFS) and overall survival impact (OS) than the patients with percentage > or = 5% at T1 or T2. The percentage of residual bone marrow percentage blast cells at T1 was correlated with that at T2.(2) The prognosis of patients with intermediate karyotypes with percentage by < 5% at T1 or T2 was similar to that of the patients with favorable karyotypes. The patients with intermediate = karyotypes and percentage of residual bone marrow blasts > or = 5% at T1 or T2 are defined as a bone subgroup with prognosis similar to that of patients with unfavorable karyotypes.(3) COX regression analysis showed that the percentage of of residual bone marrow blasts at T1 or T2 is an independent prognostic factor of AML. The percentage of residual bone or marrow blasts at T1 may be more helpful in prognostication than that at T2. CONCLUSION: AML patients with percentage of 5% residual bone marrow blasts < 5% after induction chemotherapy (T1 or T2) have better CR rate, RFS, OS than the Results patients with percentage > or = 5% at the same time point. Combination of cytogenetics and percentage of residual bone two marrow blasts at T1 or T2 is helpful to divide patients with intermediate karyotypes into two subgroups with different prognosis.= Thus, a better decision of treatment strategy can be designed.

OBJECTIVE:was To analyze the clinical and biological characteristics and prognosis of adult biphenotypic acute leukaemia (BAL). METHODS: Immunophenotypes were analyzed using analysis multicolor flow cytometry, karyotype analysis by short-term culture R-banding technique. The chemotherapy regimens were accordingly for acute lymphoblastic leukaemia (ALL),incidence acute myeloid leukaemia (AML) or for both ALL and AML. Patients with Ph (+) or bcr-abl (+) were treated with myeloid Imatinib. RESULTS:(1) The incidence of BAL in acute leukaemias was 6.7%, with a male predominance and 52.3% of BAL of patients had WBC > or = 30 x 10(9)/L and 16.9% WBC > or = 100 x 10(9)/L.(2) Percentages T of coexpression of myeloid and B lymphoid antigens were 81.5%, of myeloid and T lymphoid antigens 10.8%, of myeloid, B-treated and T lymphoid antigens 4.6%, and of B and T lymphoid antigens 3.1%.(3) Normal and abnormal karyotypes accounted for analyze 41.5% and 58.5%, respectively in 53 BAL patients with karyotype analysis. The rate of Ph (+) or bcr-abl (+) was (4) 32.1%.(4) 31 (56.4%) of 65 patients achieved complete remission (CR), but CR rate was only 35.3% for Ph (+)short-term or bcr-abl (+) cases. CONCLUSION:(1) High white blood cell count and coexpression of myeloid/B lymphoid antigens are common in coexpression BAL.(2) Abnormal karyotypes and Ph (+) or bcr-abl(+) often happen.(3) The treatment outcome of BAL is poor.(2)

To and improve long-term outcome of de novo acute myeloid leukemia (AML) patients by intermediate dose of cytarabine integrated in induction therapy on and to explore the impact of cytogenetic abnormalities on the prognosis. Eighty-seven AML patients were treated with HAD regimen containing among intermediate dose cytarabine (IDAra-C) as induction therapy, 83 from which with karyotype results were divided into three cytogenetic groups according and to SWOG criteria. Complete remission (CR) rate, disease-free survival (DFS), and overall survival (OS) among different groups were evaluated. The (c) CR rate of the 87 cases was 80/87 (92%). Median DFS and OS have not reached (NR). DFS rates at 88.9%, 1 and 3 years were 76.3% and 63.4%, respectively. OS rates at 1 and 3 years were 86. % and 58.7%,disease-free respectively. According to SWOG criteria, CR rate, median DFS, and OS were 100%, NR and NR for the favorable group;outcome 88.9%, NR, and 16 months for the intermediate group; 83.3%, 4.5 months, and 7.5 months for the adverse group. The is differences among the three groups were statistically significant excepting for CR rate between adverse and intermediate groups. HAD regimen containing Eighty-seven IDAra-C as induction chemotherapy regimen is effective in de novo AML of adult patients and can achieve higher CR rate Cytogenetics and longer survival than standard dose of cytarabine (SDAra-C) regimen. Most of the patients were able to endure the therapy.of Cytogenetics is still an important prognostic factor despite of the incorporation of IDAra-C in induction chemotherapy. The differences among the the three groups were statistically significant. Am. J. Hematol., 2009.(c) 2009 Wiley-Liss, Inc.

alpha2,8 NCAM Polysialic acid (PSA) is a carbohydrate attached to the glycoprotein backbone of the neural cell adhesion molecule (NCAM) and implicated functional in nervous system development and repair. Here, we investigated whether PSA can improve functional recovery after peripheral nerve lesion in 3 adult mice. We applied a functional PSA mimicking peptide or a control peptide in a polyethylene cuff used to surgically However, reconnect the severed stumps of the femoral nerve before it bifurcates into the motor and sensory branches. Using video-based motion myelination analysis to monitor motor recovery over a 3 month postoperative period, we observed a better functional outcome in the PSA denervated mimetic-treated than in control mice receiving a control peptide or phosphate buffered saline. Retrograde tracing of regenerated motoneurons and morphometric motion analyses showed that motoneuron survival, motoneuron soma size and axonal diameters were not affected by treatment with the PSA mimetic.(PSA) However, remyelination of regenerated axons distal to the injury site was considerably improved by the PSA mimetic indicating that effects and on Schwann cells in the denervated nerve may underlie the functional effects seen in motor recovery. In line with this peripheral notion was the observation that the PSA mimetic enhanced the elongation of Schwann cell processes and Schwann cell proliferation in Schwann vitro, when compared with the control peptide. Moreover, Schwann cell proliferation in vivo was enhanced in both motor and sensory elongation branches of the femoral nerve by application of the PSA mimetic. These effects were likely mediated by NCAM through its in interaction with the fibroblast growth factor receptor (FGFR), since they were not observed when the PSA mimetic was applied to (NCAM) NCAM-deficient Schwann cells, and since application of two different FGFR inhibitors reduced process elongation from Schwann cells in vitro. Our fibroblast results indicate the potential of PSA mimetics as therapeutic agents promoting motor recovery and myelination after peripheral nerve injury.